Jacobs Levy Equity Management’s Traws Pharma TRAW Stock Holding History

Jacobs Levy Equity Management’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1	Closed	-$65K	–	1192
2015 Q4	$65K	Hold	1	–	–	﹤0.01%	770
2015 Q3	$92K	Hold	1	–	–	﹤0.01%	763
2015 Q2	$139K	Buy	+1	New	+$143K	﹤0.01%	753

Other funds holding TRAW

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

WMSA

Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jacobs Levy Equity Management's TRAW Position: Q1 2016 in Review

Jacobs Levy Equity Management sold out of Traws Pharma (TRAW) in Q1 2016, closing a stake of 1 share — an estimated $65K sold.

Jacobs Levy Equity Management first reported a position in TRAW in Q2 2015 and held it in 3 quarters. The position peaked at $139K in Q2 2015. 11 funds tracked by Wall St. Rank hold TRAW as of Q1 2016.

Jacobs Levy Equity Management reported no remaining Traws Pharma position as of Q1 2016 after selling out during the quarter.
Jacobs Levy Equity Management sold 1 Traws Pharma share in Q1 2016, an estimated $65K.
Jacobs Levy Equity Management first reported a position in Traws Pharma in Q2 2015 and held it in 3 quarters.
Jacobs Levy Equity Management's Traws Pharma position peaked at $139K in Q2 2015.
11 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2016.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2016, filed 16 May 2016.